Serum direct bilirubin < 2 mg/dl or serum total bilirubin =< 3; NOTE: the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration
Obtained =< 48 hours prior to registration: Serum direct bilirubin < 2 mg/dL or serum total bilirubin =< 3
Serum bilirubin must be ? 2.0 mg/dl
Serum bilirubin < 2 mg/dL
Serum bilirubin values < 2.0 mg/dL
Serum bilirubin levels =< 1.5 mg/dL
Serum bilirubin =< 1.5 mg/dL
Patients must have a serum bilirubin =< 2.0 mg/dl
Serum phosphate less than 2.0 mg/dL
Serum total bilirubin\t ? 2 mg/dl (biliary stent is allowed) within 10 days prior to “on study” status
Serum direct bilirubin =< 2 mg/dL (34 umol/L) within 21 days prior to initiation of therapy
Serum bilirubin =< 1.5 mg/dL
Serum bilirubin =< 3.0 mg/dL.
Within 14 days prior to planned start of treatment: Total serum bilirubin =< 2.2 mg/dL
Serum bilirubin =< 2.0 mg/dl
Serum bilirubin >= 2 mg/dL
Serum bilirubin =< 2.0 mg/dl
Serum bilirubin < 1.5 mg/dl
Serum total bilirubin less than 2.5 mg/dl; patients with elevations of serum total bilirubin up to 10 mg/dl may be considered for participation if such elevations are thought to be due to liver involvement by malignancy; however, in these latter patients, if the bilirubin (BR) level does not decrease to less than or equal to 2.5 mg/dl after induction chemotherapy, eligibility for the transplant (research) phase will be at the discretion of the PI
Serum bilirubin =< 2.0 mg/dl; some patients with minor deviations may be accepted on protocol after discussion with the PI
Serum bilirubin < or =< 2.0 mg/dl
Serum bilirubin > 1.2 mg/dl
Serum bilirubin =< 3.0 mg/dL
Patients must have a serum bilirubin =< 2.0 mg/dl
Serum bilirubin must be ? 2.0 mg/dl
Serum bilirubin > 3.0 mg/dL.
Serum bilirubin > 2.0 mg/dl (unless segmental infusion is planned)
Serum direct bilirubin =< 2 mg/dL (34 umol/L)
Serum bilirubin =< 2.0 g/dL
Relapsed/refractory MCL: Serum bilirubin < 1.5 mg/dl
Newly diagnosed MCL: Serum bilirubin < 1.5 mg/dl
RECIPIENT: Serum conjugated bilirubin < 2.5 mg/dl
Have serum creatinine <1.6 mg/dL, INR < 1.5 U, absolute neutrophil count (ANC) > 1 x 109/L , platelets ? 100 x 109/L , hemoglobin ? 10 mg/dL, ALT and AST ? 3 x ULN, bilirubin ? 1.5 x ULN
Patients must have a serum bilirubin =< 2.0 mg/dl
Serum total bilirubin > 2.5 mg/dl; if the abnormal liver function is attributable to liver involvement by malignancy, patients may be eligible with serum total bilirubin up to 5.0 mg/dl, provided the patient has no evidence of impending hepatic failure (encephalopathy or prothrombin time > 2 times the upper limit of normal)
Serum bilirubin > 3.0 mg/dl\r\n* In some cases where there is an elevated bilirubin, and the tumor may be isolated from a vascular standpoint, treatment may proceed
Serum bilirubin > 3.0 mg/dl; * In some cases where there is an elevated bilirubin, and the tumor may be isolated from a vascular standpoint, treatment may proceed
Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 5.0 mg/dL is acceptable
Total serum bilirubin concentration >3.0 mg/dL UNLESS attributed to GvHD
Serum bilirubin < 1.5 mg/dl performed within 60 days of enrollment
Serum bilirubin values < 2 mg/dL
Serum bilirubin greater than 1.5 mg/dl
Serum bilirubin > 3.0 mg/dl
Serum bilirubin < 1.5 mg/dl
Serum bilirubin >= 6 mg/dl
Serum bilirubin < 2 mg/dL
Patients must have a serum bilirubin =< 2.0 mg/dl
Serum bilirubin =< 3.0 mg/dl for Group A
Serum bilirubin =< 2.0 mg/dl for Group B or C (unless segmental infusion can be performed, then serum bilirubin =< 3.0 mg/dl allowed)
Serum bilirubin =< 1.5 mg/dL; patients with Gilbert's disease: serum bilirubin < 5 mg/dL
Serum bilirubin =< 2.0 mg/dl
Patients must have a serum bilirubin =< 1.5 mg/dl
If the patient is to be treated with cisplatin, the serum bilirubin of =< 2.0 mg%
Serum bilirubin < 1.5 mg/dL
Serum bilirubin: ? 1.2 mg/dL
Serum bilirubin < 1.5 mg/dl
Serum bilirubin < 1.5 mg/dl
Serum direct bilirubin < 2 mg/dL (34 Omol/L) within 30 days prior to cycle 1 day 1
Serum direct bilirubin < 2 mg/dL (34 Omol/L) within 7 days of time of consent
Serum bilirubin level of less than 1.5 mg/dl
Serum bilirubin < 1.5 mg/dl
Serum bilirubin =< 1.5 mg/dL
Serum bilirubin =< 2.0 mg/dl, within 4 weeks prior to first immunization
Serum bilirubin =< 2.0 mg/dl
Serum total bilirubin less than 2.5 mg/dl; patients with elevations of serum total bilirubin up to 10 mg/dl may be considered for participation if such elevations are thought to be due to liver involvement by malignancy; however, in these latter patients, if these values do not decrease to less than or equal to 2.5 times the upper limit of normal during induction chemotherapy, such patients will not be eligible for the transplant phase of the protocol, and will thus be taken off study
Serum bilirubin < 1.5 mg/dl
No impairment of hepatic function (serum bilirubin level of less than 1.2 mg/dl)
Patients must have adequate hepatic function as documented by a serum bilirubin less than or equal to 2.5 mg/dL.
Serum creatinine < 1.6 mg/dL. Serum bilirubin < 2X upper limit of normal.
Abnormal liver function tests: Serum aspartate transaminase (AST/SGOT) or alanine transaminase ( ALT/SGPT) 2 x upper limit of normal (ULN). Serum bilirubin. Total bilirubin > 2.0 mg/dL (34 µmol/L), conjugated bilirubin > 0.8 mg/dL.
Serum direct bilirubin =< 2 mg/dL (34 umol/L) within 14 days prior to randomization
Serum bilirubin =< 1.5 mg/dL; except for patients with Gilbert's disease: serum bilirubin < 5 mg/dL
Serum bilirubin levels =< 1.5 mg/dL
Serum direct bilirubin =< 2.0 mg/dl
Serum bilirubin < 2.0 mg/dL
Serum bilirubin < 3 mg/dl
Serum bilirubin > 25 umol/L (1.5 mg/dL)
Serum bilirubin =< 1.0 mg/dL
Serum bilirubin =< 2.0 mg/dL within 28 days prior to registration
Serum bilirubin must be ? 2.0 mg/dl
Serum bilirubin must be ? 2.0 mg/dl
Serum bilirubin =< 2.0 mg/dl
Serum bilirubin =< 1.5 mg/dL
